🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer

RecruitingNAAges any - 45 YearsFemalePeking University People's Hospital
NCT06468215 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Endometrioid adenocarcinoma G2, diagnosis by pathological. * The lesion is limited to the endometrium. * FIGO (2009) staging is IA. * Age less than 45. * Strongly request to preserve fertility. * Sign informed consent. Exclusion Criteria: * The tumor has invaded the muscle layer. * FIGO (2009) stage IB or higher. * Endometrioid adenocarcinoma G1, G3, or non-endometrioid cancer * There are malignant tumors in other systems. * Have contraindications for conservative treatment or drug use. * Have been judged by the researcher to be unsuitable for childbearing.
💊

What it tests

  • Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
📍

Where

1 site
Peking University People's Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy